SCHEMBL5544609

SCHEMBL5544609

O=[C]CCN1CCN(C(=O)Nc2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.60
PRKAB2 O43741 4/20 0.60
PRKAG1 P54619 4/20 0.60
PRKAA2 P54646 4/20 0.60
PRKAA1 Q13131 4/20 0.60
PRKAG3 Q9UGI9 4/20 0.60
PRKAG2 Q9UGJ0 4/20 0.60
PRKAB1 Q9Y478 4/20 0.60
CCR2 P41597 1/20 0.53
KCNH2 Q12809 1/20 0.53
MAPT P10636 2/20 0.53
NAMPT P43490 1/20 0.52
TRPV1 Q8NER1 6/20 0.52
CNR1 P21554 1/20 0.52
CNR2 P34972 1/20 0.52
HPGDS O60760 1/20 0.52
LMNA P02545 1/20 0.50
KMT2A Q03164 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536453 0.86 KMT2A (0.58) FAAHPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL5537720 0.85 CA1 (0.56) KCNH2MAPTLMNAKMT2A
SCHEMBL5535035 0.84 ACHE (0.66) TRPV1LMNAKMT2ASMN1; SMN2
SCHEMBL5542340 0.83 FAAH (0.59) FAAHCCR2KCNH2MAPTTRPV1
SCHEMBL5546588 0.83 NPC1 (0.58) FAAHMAPT
SCHEMBL5541733 0.83 FAAH (0.65) FAAHMAPTNPSR1
SCHEMBL5544612 0.82 FAAH (0.60) FAAHPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL5546036 0.80 MAPT (0.70) FAAHPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL15134839 0.80 EPHX2 (0.69) FAAHPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL4559682 0.78 MAPT (0.73) FAAHPRKAB2PRKAG1PRKAA2PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 FAAH 4363/4885PRKAB2 3290/4885PRKAG1 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.